Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: A case-control study

Urology

Volumn 77, Issue 4, 2011, Pages 934-940

  Bylow, Kathryn ^a   Hemmerich, Joshua ^a   Mohile, Supriya G ^a   Stadler, Walter M ^a   Sajid, Saleha ^a   Dale, William ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIANDROGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; CANCER RECURRENCE; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DISABILITY; ERYTHROCYTE SEDIMENTATION RATE; FALLING; FRAIL ELDERLY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL PERFORMANCE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; SHORT PHYSICAL PERFORMANCE BATTERY;

ACCIDENTAL FALLS; AGED; CASE-CONTROL STUDIES; FRAIL ELDERLY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OBESITY; PROSTATIC NEOPLASMS;

EID: 79953849203     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.11.024     Document Type: Article

References (30)

1. Ries LAG, Kosary CL, Hankey BF, et al. SEER Cancer Statistics Review, 1973-1996. Baltimore, MD: National Cancer Institute; 1999.
2. Newschaffer CJ, Otani K, McDonald MK, et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92:613-621. (Pubitemid 30321303)
3. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61:32-38. (Pubitemid 36349540)
4. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599-603. (Pubitemid 34158224)
5. Bylow K, Dale W, Mustian K, et al. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology. 2008;72:422-427.
6. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164. (Pubitemid 40096612)
7. Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615-1624.
8. Mohile SG, Petrylak DP. Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer. Curr Oncol Rep. 2006;8:213-220.
9. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171:1141-1147. (Pubitemid 38327544)
10. Walsh PC, DeWeese TL, Eisenberger MA. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol. 2001;166:508-515; Discussion: 515-516.
11. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-M156. (Pubitemid 32187141)
12. Cigolle CT, Ofstedal MB, Tian Z, et al. Comparing models of frailty: the Health and Retirement Study. J Am Geriatr Soc. 2009;57:830-839.
13. Sarkisian CA, Gruenewald TL, John-Boscardin W, et al. Preliminary evidence for subdimensions of geriatric frailty: the Macarthur study of successful aging. J Am Geriatr Soc. 2008;56:2292-2297.
14. Cesari M, Penninx BW, Pahor M, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59:242-248. (Pubitemid 38375337)
15. Leng S, Chaves P, Koenig K, et al. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002;50:1268-1271. (Pubitemid 34774552)
16. Reuben DB, Cheh AI, Harris TB, et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc. 2002;50:638-644. (Pubitemid 34298751)
17. Bylow K, Mohile SG, Stadler WM, et al. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? Cancer. 2007;110:2604-2613.
18. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36:428-434. (Pubitemid 11070078)
19. Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556-561.
20. Blaum CS, Xue QL, Michelon E, et al. The association between obesity and the frailty syndrome in older women: the women's Health and Aging Studies. J Am Geriatr Soc. 2005;53:927-934. (Pubitemid 41647587)
21. Villareal DT, Banks M, Siener C, et al. Physical frailty and body composition in obese elderly men and women. Obes Res. 2004;12:913-920. (Pubitemid 41202391)
22. Bylow K, Mohile SG, Stadler WM, et al. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? a conceptual review. Cancer. 2007.
23. Tinetti ME, Williams CS. The effect of falls and fall injuries on functioning in community-dwelling older persons. J Gerontol A Biol Sci Med Sci. 1998;53:M112-M119. (Pubitemid 28136149)
24. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166:465-471.
25. Mohile SG, Bylow K, Dale W, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007;109:802-810. (Pubitemid 46233244)
26. Mohile SG, Xian Y, Dale W, et al. Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst. 2009;101:1206-1215.
27. Clay CA, Perera S, Wagner JM, et al. Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther. 2007;87:1325-1333. (Pubitemid 47584278)
28. Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176:2443-2447. (Pubitemid 44665959)
29. Hussain S, Breunis H, Timilshina N, et al. Falls in men on androgen deprivation therapy for prostate cancer. J Geriatr Oncol. 2010;1:32-30.
30. Dale W. Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer. J Clin Oncol. 2009;27:3420-3422.